AbbVie Inc. (ABBV)

93.49
NYSE : Health Technology
Prev Close 95.55
Day Low/High 93.43 / 96.11
52 Wk Low/High 69.38 / 125.86
Avg Volume 8.95M
Exchange NYSE
Shares Outstanding 1.59B
Market Cap 151.63B
EPS 3.30
P/E Ratio 24.01
Div & Yield 3.84 (3.00%)

Latest News

AbbVie Announces New Undetectable Minimal Residual Disease Data From Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial Of Venetoclax In Combination With Rituximab At 23rd European Hematology Association Annual Congress

AbbVie Announces New Undetectable Minimal Residual Disease Data From Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial Of Venetoclax In Combination With Rituximab At 23rd European Hematology Association Annual Congress

- 83 percent (n=100) of 121 patients who achieved undetectable minimal residual disease (uMRD) at the end of combination therapy with VenR (n=194), maintained uMRD and were progression-free at 13.8 months of follow-up[1]

AbbVie Declares Quarterly Dividend

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., June 14, 2018 /PRNewswire/ -- The board of directors of AbbVie Inc.

AbbVie Presents Additional Outcomes Data From Three Upadacitinib Phase 3 Studies In Rheumatoid Arthritis At The Annual European Congress Of Rheumatology (EULAR 2018)

AbbVie Presents Additional Outcomes Data From Three Upadacitinib Phase 3 Studies In Rheumatoid Arthritis At The Annual European Congress Of Rheumatology (EULAR 2018)

- Upadacitinib showed improvements in physical function, a measure that assesses patients' ability to perform daily activities and level of disability(1,2,3)

AbbVie Announces U.S. FDA Approval Of VENCLEXTA® (venetoclax Tablets) In Combination With Rituximab As A Fixed Duration Treatment For Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy

AbbVie Announces U.S. FDA Approval Of VENCLEXTA® (venetoclax Tablets) In Combination With Rituximab As A Fixed Duration Treatment For Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy

-- In the MURANO Phase 3 clinical trial, the VENCLEXTA® (venetoclax tablets) plus rituximab combination showed a significant improvement in progression-free survival (PFS) for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients, reducing the risk of disease progression or death by 81 percent when compared to a standard of care chemoimmunotherapy regimen, bendamustine plus rituximab (1)

Upadacitinib Monotherapy Meets All Primary And Ranked Secondary Endpoints Versus Methotrexate In A Phase 3 Study In Rheumatoid Arthritis

Upadacitinib Monotherapy Meets All Primary And Ranked Secondary Endpoints Versus Methotrexate In A Phase 3 Study In Rheumatoid Arthritis

- In SELECT-EARLY, upadacitinib monotherapy (15/30 mg, once-daily) met both primary endpoints, with 52/56 percent of methotrexate-naïve patients achieving ACR50 at week 12 and 48/50 percent achieving clinical remission at week 24, respectively(1)

AbbVie Announces Final Results Of Tender Offer

AbbVie Announces Final Results Of Tender Offer

NORTH CHICAGO, Ill., June 4, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, at the end of May 29, 2018.

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates Of Responses In Patients With Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates Of Responses In Patients With Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

- Approximately nine out of 10 of the first CLL patients treated achieved responses with no detectable minimal residual disease (MRD) based on a specific test to detect cancer cells in the bone marrow

Good Job Growth, Low Inflation: Cramer's 'Mad Money' Recap (Friday 6/1/18)

Good Job Growth, Low Inflation: Cramer's 'Mad Money' Recap (Friday 6/1/18)

Jim Cramer says the market like this economy; he has your game plan for next week.

Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes In Waldenström's Macroglobulinemia (WM), A Rare Form Of Blood Cancer, In Combination With Rituximab Versus Rituximab Alone

Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes In Waldenström's Macroglobulinemia (WM), A Rare Form Of Blood Cancer, In Combination With Rituximab Versus Rituximab Alone

- Study data suggest IMBRUVICA plus rituximab could provide a new option across all lines of WM treatment, regardless of prognostic or genotypic factors

AbbVie To Present New Data From Several Investigational Studies Of Venetoclax As Monotherapy Or In Combination For The Management Of A Number Of Difficult-to-Treat Blood Cancers At 23rd European Hematology Association (EHA) Annual Congress

- Results from a sub-analysis of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) who achieved undetectable minimal residual disease in the Phase 3 MURANO investigational study of venetoclax in combination with rituximab will be featured in an oral presentation

The Largest U.S. Cannabis Company Finds a Home on a Canadian Exchange

The Largest U.S. Cannabis Company Finds a Home on a Canadian Exchange

MedMen is now selling shares on the Canadian Securities Exchange. Here's why it still isn't possible for the $1.65 billion company to list in its home country.

AbbVie Becomes #233 Most Shorted S&P 500 Component, Replacing Mettler-Toledo International

The most recent short interest data has been released for the 05/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

President Trump's appetite for TV and ratings is legendary and now the administration wants to require drug company TV ads to include the list price of prescription drugs.

When the Stock Is the Only Option

When the Stock Is the Only Option

Options spreads aren't tradable with some small biotechs, making shares the only way to play.

AbbVie Donates $100 Million To Strengthen Access To Healthcare, Housing For Hurricane-Ravaged Puerto Rico

Partners Direct Relief and Habitat for Humanity International will focus on rebuilding primary healthcare system and ensuring access to affordable, disaster-resilient housing, respectively

AbbVie To Show Progress And Growth In Oncology Research At The American Society Of Clinical Oncology 2018 Annual Meeting

- More than 30 abstracts accepted across hematologic malignancies, solid tumors and other oncology-related diseases

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names

4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names

KLA-Tencor, Microsoft and Intel all report earnings after the close Thursday.

AbbVie Submits Biologics License Application To U.S. FDA For Investigational Treatment Risankizumab For Moderate To Severe Plaque Psoriasis

- In clinical studies, more than half of patients receiving risankizumab achieved complete skin clearance (PASI 100) at one year (52 weeks) (1)

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

TheStreet Quant Rating: A- (Buy)